Payment overview · 2025
General Payments
$260.88
14 reported records · 7 companies
Healthcare provider profile · identity verified
David J Riddle, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BIRMINGHAM, AL · NPI 1215102660
Verified facts
What the public records show
CMS Open Payments records show David J Riddle, MD received $260.88 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $65.99 | 25.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.48 | 17.8% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $39.20 | 15.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.11 | 14.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $32.68 | 12.5% | 2 | 2025 |
| Siemens Medical Solutions USA, Inc. | Unresolved — no canonical attribution shown | $20.82 | 8.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.60 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $260.88 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $65.99 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.48 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $39.20 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $38.11 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.11 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $32.68 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.20 | 1 | 2025 |
Source payment records
|
|||||
| IMMULITE 1000 Immunoassay System Normalized: immulite 1000 immunoassay system |
Device | Siemens Medical Solutions USA, Inc. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 106 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
106 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 396 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 313 | 97 |
| Atorvastatin Calcium | Atorvastatin Calcium | 307 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 215 | 54 |
| Lisinopril | Lisinopril | 213 | 59 |
| Montelukast Sodium | Montelukast Sodium | 182 | 60 |
| Ezetimibe | Ezetimibe | 162 | 49 |
| Losartan Potassium | Losartan Potassium | 162 | 53 |
| Omeprazole | Omeprazole | 157 | 50 |
| Trazodone Hcl | Trazodone Hcl | 150 | 56 |
| Metformin Hcl Er | Metformin Hcl | 146 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 40 |
| Ozempic | Semaglutide | 106 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 100 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 31 |
| Bupropion Xl | Bupropion Hcl | 94 | 32 |
| Gabapentin | Gabapentin | 94 | 32 |
| Sertraline Hcl | Sertraline Hcl | 92 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 26 |
| Donepezil Hcl | Donepezil Hcl | 71 | 19 |
| Jardiance | Empagliflozin | 69 | 19 |
| Metformin Hcl | Metformin Hcl | 67 | 21 |
| Tramadol Hcl | Tramadol Hcl | 67 | 20 |
| Buspirone Hcl | Buspirone Hcl | 65 | 22 |
| Famotidine | Famotidine | 64 | 24 |
| Mounjaro | Tirzepatide | 64 | 12 |
| Pregabalin | Pregabalin | 61 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 16 |
| Potassium Chloride | Potassium Chloride | 54 | 20 |
| Meloxicam | Meloxicam | 52 | 24 |
| Eliquis | Apixaban | 49 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 14 |
| Valacyclovir | Valacyclovir Hcl | 49 | 16 |
| Carvedilol | Carvedilol | 46 | 16 |
| Trulicity | Dulaglutide | 46 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 45 | 24 |
| Alendronate Sodium | Alendronate Sodium | 44 | 14 |
| Finasteride | Finasteride | 43 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 18 |
| Allopurinol | Allopurinol | 41 | 12 |
| Chlorthalidone | Chlorthalidone | 38 | 11 |
| Furosemide | Furosemide | 37 | 15 |
| Lorazepam | Lorazepam | 36 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 15 |
| Rybelsus | Semaglutide | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 31 | suppressed |
| Simvastatin | Simvastatin | 31 | suppressed |
| Clonazepam | Clonazepam | 29 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Prednisone | Prednisone | 14 | 13 |
| Celecoxib | Celecoxib | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $260.88 · 14 records | Novo Nordisk Inc | Dexcom G6 Transmitter, IMMULITE 1000 Immunoassay System, NURTEC ODT, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, Veozah, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error